Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

Abstract

Objective To evaluate the safety and tolerability of multiple intravenous (IV) doses of sifalimumab in adults with moderate‐to‐severe systemic lupus erythematosus (SLE). Methods In this multicenter, double‐blind, placebo‐controlled, sequential dose‐escalation study, patients were randomized 3:1 to receive IV sifalimumab (0.3, 1.0, 3.0, or 10.0 mg/kg) or placebo every 2 weeks to week 26, then followed up for 24 weeks. Safety assessment included recording of treatment‐emergent adverse events (AEs) and serious AEs. Pharmacokinetics, immunogenicity, and pharmacodynamics were evaluated, and disease activity was assessed. Results Of 161 patients, 121 received sifalimumab (26 received 0.3 mg/kg; 25, 1.0 mg/kg; 27, 3.0 mg/kg; and 43, 10 mg/kg) and 40 received placebo. Patients were predominantly female (95.7%). At baseline, patients had moderate‐to‐severe disease activity (mean SLE Disease Activity Index score 11.0), and most (75.2%) had a high type I interferon (IFN) gene signature. In the sifalimumab group versus the placebo group, the incidence of ≥1 treatment‐emergent AE was 92.6% versus 95.0%, ≥1 serious AE was 22.3% versus 27.5%, and ≥1 infection was 67.8% versus 62.5%; discontinuations due to AEs occurred in 9.1% versus 7.5%, and death occurred in 3.3% (n = 4) versus 2.5% (n = 1). Serum sifalimumab concentrations increased in a linear and dose‐proportional manner. Inhibition of the type I IFN gene signature was sustained during treatment in patients with a high baseline signature. No statistically significant differences in clinical activity (SLEDAI and British Isles Lupus Assessment Group score) between sifalimumab and placebo were observed. However, when adjusted for excess burst steroids, SLEDAI change from baseline showed a positive trend over time. A trend toward normal complement C3 or C4 level at week 26 was seen in the sifalimumab groups compared with baseline. Conclusion The observed safety/tolerability and clinical activity profile of sifalimumab support its continued clinical development for SLE.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 36

1. 1.

   Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 1999;42:1785-96.

   Not in our library10.1002/1529-0131(199909)42:9<1785::aid-anr1>3.0.co;2-#

2. 2.

   Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929-39.

   Not in our library10.1056/nejmra071297

3. 3.

   Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195-205.

   Not in our library10.1136/ard.2007.070367

4. 4.

   Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363-9.

   Not in our library10.1002/art.1780390303

5. 5.

   To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum. 2005;52:4003-10.

   Not in our library10.1002/art.21414

6. 6.

   Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore. 2007;36:115-22.

   Not in our library

7. 7.

   Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol. 2009;5:400-4.

   Not in our library10.1038/nrrheum.2009.106

8. 8.

   Clarke AE, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, for the Tri-nation Study Group, et al. The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford). 2004;43:1016-24.

   Not in our library10.1093/rheumatology/keh229

9. 9.

   Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, the BLISS-52 Study Group, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-31.

   Not in our library10.1016/s0140-6736(10)61354-2

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.

    Kalunian K, Joan TM. New directions in the treatment of systemic lupus erythematosus. Curr Med Res Opin. 2009;25:1501-14.

    Not in our library10.1185/03007990902929104

12. 12.

    La Cava A. Anticytokine therapies in systemic lupus erythematosus. Immunotherapy. 2010;2:575-82.

    Not in our library10.2217/imt.10.29

13. 13.

    Obermoser G, Pascual V. The interferon-α signature of systemic lupus erythematosus. Lupus. 2010;19:1012-9.

    Not in our library10.1177/0961203310371161

14. 14.

    Ronnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23:113-21.

    Not in our library10.1016/j.smim.2011.01.009

15. 15.

    Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer. 1991;68:1536-7.

    Not in our library10.1002/1097-0142(19911001)68:7<1536::aid-cncr2820680713>3.0.co;2-b

16. 16.

    Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy [review]. Arthritis Rheum. 2000;43:1431-42.

    Not in our library10.1002/1529-0131(200007)43:7<1431::aid-anr3>3.0.co;2-e

17. 17.

    Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000;9:664-71.

    Not in our library10.1191/096120300674499064

18. 18.

    Dall'Era MC, Cardarelli PM, Preston BT, Witte A, Davis JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005;64:1692-7.

    Not in our library10.1136/ard.2004.033753

19. 19.

    Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009;60:3098-107.

    Not in our library10.1002/art.24803

20. 20.

    Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70:2029-36.

    Not in our library10.1136/ard.2011.150326

21. 21.

    Criswell LA. The genetic contribution to systemic lupus erythematosus. Bull NYU Hosp Jt Dis. 2008;66:176-83.

    Not in our library

22. 22.

    Sigurdsson S, Goring HH, Kristjansdottir G, Milani L, Nordmark G, Sandling JK, et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet. 2008;17:872-81.

    Not in our library10.1093/hmg/ddm359

23. 23.

    Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Theofilopoulos AN. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med. 2003;197:777-88.

    Not in our library10.1084/jem.20021996

24. 24.

    Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, et al. IFNα kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A. 2009;106:5294-9.

    Not in our library10.1073/pnas.0900615106

25. 25.

    Yao Y, Richman L, Higgs BW, Morehouse CA, de Los Reyes M, Brohawn P, et al. Neutralization of interferon-α/β–inducible genes and downstream effect in a phase I trial of an anti–interferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1785-96.

    Not in our library10.1002/art.24557

26. 26.

    Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, for the Lupus Interferon Skin Activity (LISA) Study Investigators, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70:1905-13.

    Not in our library10.1136/ard.2010.144485

27. 27.

    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.

    Not in our library10.1002/art.1780251101

28. 28.

    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum. 1997;40:1725.

    Not in our library10.1002/art.1780400928

29. 29.

    Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, for the OC-SELENA Trial, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550-8.

    Not in our library10.1056/nejmoa051135

30. 30.

    Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86:447-58.

    Not in our library

31. 31.

    Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:902-6.

    Not in our library10.1093/rheumatology/keh624

32. 32.

    Yao Y, Higgs BW, Morehouse C, de los Reyes M, Trigona W, Brohawn P, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics. 2009;2009:374312.

    Not in our library10.4061/2009/374312

33. 33.

    Yao Y, Higgs BW, Richman L, White B, Jallal B. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:S6.

    Not in our library10.1186/ar2887

34. 34.

    Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953-62.

    Not in our library10.7326/0003-4819-142-12_part_1-200506210-00004

35. 35.

    Strand V. Lessons learned from clinical trials in SLE. Autoimmun Rev. 2007;6:209-14.

    Not in our library10.1016/j.autrev.2006.08.002

36. 36.

    Eisenberg R. Why can't we find a new treatment for SLE? J Autoimmun. 2009;32:223-30.

    Not in our library10.1016/j.jaut.2009.02.006

Cited by papers we hold 4

• Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider · 2023
  Not checked
• Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease · 2020
  Not checked
• Neutrophil Extracellular Traps (NETs) Take the Central Stage in Driving Autoimmune Responses · 2020
  No notice
• Regulating IRFs in IFN Driven Disease · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.